DUBLIN – Sanofi SA remains on track to complete a fourth-quarter regulatory submission of Lixilan, a fixed-ratio combination of its basal insulin (Lantus; insulin glargine) and its glucagon-like peptide 1 (GLP-1) receptor agonist Lyxumia (lixisenatide), on the back of a positive readout from the second of two phase III trials in type 2 diabetes patients.